



PDTM Update

Date: January 30, 2026

To: Parenteral Drug Therapy Manual Users at BC Women's Hospital + Health Centre (BCW), Providence Health Care (PHC) and Vancouver Coastal Health (VCH)

From: Parenteral Drug Therapy Manual Support (pdtm@vch.ca)

The following information has been updated since October 1, 2025 through January 31, 2026; please refer to the on-line manual for the most recent version(s):

Document	Summary of changes
alemtuzumab	Updated Indications section - BC Cancer restriction language
amikacin	Updated dosage section
amphotericin B lipid complex (ABELCET)	Archived
arsenic	Updated Indications section - BC Cancer restriction language
azaCITIDine	Updated Indications section - BC Cancer restriction language
BCG	Updated Indications section - BC Cancer restriction language
bendamustine	Updated Indications section - BC Cancer restriction language
bleomycin	Updated Indications section - BC Cancer restriction language
blinatumomab	Updated Indications section - BC Cancer restriction language
bortezomib	Updated Indications section - BC Cancer restriction language
brentuximab vedotin	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, and Potential Hazards of Parenteral Administration sections
busulfan	Updated Indications section - BC Cancer restriction language
CARBOplatin	Updated Indications section - BC Cancer restriction language

Lower Mainland Pharmacy Services

Document	Summary of changes
carfilzomib	Updated Indications section - BC Cancer restriction language
carmustine	Updated Indications section - BC Cancer restriction language
CISplatin	Updated Indications section - BC Cancer restriction language
cladribine	Updated Indications section - BC Cancer restriction language
COVID-19 mRNA vaccine	Updated Alternate Names, Reconstitution & Stability, and Dosage sections
crisantaspase recombinant (RYLAZE)	Updated Indications section - BC Cancer restriction language
cyclophosphamide	Updated Indications section - BC Cancer restriction language
cytarabine	Updated Indications section - BC Cancer restriction language
dacarbazine	Updated Indications section - BC Cancer restriction language
daratumumab (IV)	Updated Indications section - BC Cancer restriction language
daratumumab (subcutaneous)	Updated Indications section - BC Cancer restriction language
DAUNOrubicin	Updated Indications section - BC Cancer restriction language
DAUNOrubicin liposomal-cytarabine liposomal	Updated Indications section - BC Cancer restriction language
degarelix	Updated Indications section - BC Cancer restriction language
denosumab	Updated Indications section - BC Cancer restriction language
dexrazoxane	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections
DOXOrubicin	Updated Indications section - BC Cancer restriction language
DOXOrubicin pegylated liposomal	Updated Indications section - BC Cancer restriction language
epcoritamab	Updated Indications section - BC Cancer restriction language
epirubicin	Updated Indications section - BC Cancer restriction language
etoposide	Updated Indications section - BC Cancer restriction language
fentanyl	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections
fludarabine	Updated Indications section - BC Cancer restriction language

Lower Mainland Pharmacy Services

Document	Summary of changes
fluorouracil	Updated Indications section - BC Cancer restriction language
fosfomicin	New monograph
gemcitabine	Updated Indications section - BC Cancer restriction language
gemtuzumab ozogamicin	Updated Indications section - BC Cancer restriction language
gentamicin	Updated Reconstitution & Stability, Compatibility, Preparation & Administration, and Dosage sections
goserelin long acting	Updated Indications section - BC Cancer restriction language
hydrocortisone	Updated Preparation & Administration section
hydroxocobalamin	Updated Reconstitution & Stability section
ifosfamide	Updated Indications section - BC Cancer restriction language
inotuzumab ozogamicin	Updated Indications section - BC Cancer restriction language
irinotecan	Updated Indications section - BC Cancer restriction language
isatuximab	Updated Indications section - BC Cancer restriction language
lacosamide	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, and Dosage sections
letermovir	New monograph
leuprolide long acting	Updated Indications section - BC Cancer restriction language Updated Title of monograph (previously leuprolide), Alternate Names, Reconstitution & Stability, Preparation & Administration, and Dosage sections
melphalan	Updated Indications section - BC Cancer restriction language
meropenem	Updated Reconstitution & Stability section Added Drug Delivery Systems - DUPLEX containers page link
methotrexate	Updated Indications, Compatibility, Dosage and Important Implications sections
mitomycin	Updated Indications section - BC Cancer restriction language
mitoXANTRONE	Updated Indications section - BC Cancer restriction language
mogamulizumab	Updated Indications section - BC Cancer restriction language

Lower Mainland Pharmacy Services

Document	Summary of changes
nelarabine	Updated Indications section - BC Cancer restriction language
oBINutuzumab	Updated Indications section - BC Cancer restriction language
ondansetron	Updated Compatibility, Preparation & Administration, and Dosage sections
oxaliplatin	Updated Indications section - BC Cancer restriction language
oxytocin	Updated Dosage section
PACLitaxel	Updated Indications section - BC Cancer restriction language
pegaspargase (ONCASPAR)	Updated Indications section - BC Cancer restriction language
pembrolizumab	Updated Indications section - BC Cancer restriction language
plerixafor	Updated Indications section - BC Cancer restriction language
polatuzumab vedotin	Updated Indications, Reconstitution & Stability, Compatibility, and Potential Hazards of Parenteral Administration sections
raltitrexed	Updated Indications section - BC Cancer restriction language
REMifentanil	Updated Dosage section
riTUXimab (IV)	Updated Indications section - BC Cancer restriction language
siltuximab	Updated Indications section - BC Cancer restriction language
tenecteplase	Updated Reconstitution & Stability and Compatibility sections
thiotepa	Updated Indications section - BC Cancer restriction language
tobramycin	Updated Reconstitution & Stability, Compatibility, and Dosage sections
tocilizumab	Updated Indications, and Reconstitution & Stability sections
topotecan	Updated Indications section - BC Cancer restriction language
tranexamic acid	Updated Preparation & Administration, and Dosage sections
trastuzumab	Updated Indications section - BC Cancer restriction language
treosulfan	Updated Indications section - BC Cancer restriction language
vinBLAStine	Updated Indications section - BC Cancer restriction language

Lower Mainland Pharmacy Services

Document	Summary of changes
vinCRISStine	Updated Indications section - BC Cancer restriction language
vinorelbine	Updated Indications section - BC Cancer restriction language